---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-002086"
form_type: "8-K"
ticker: "MRKR"
cik: "0001094038"
company_name: "Marker Therapeutics, Inc."
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T01:58:11.085231+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Marker Therapeutics prioritizes MT-601 for CAR T-relapsed lymphoma, discontinues patient-specific AML program

## Summary
- MT-601 for DLBCL patients who relapsed after CAR T: first APOLLO participant maintained complete response at 6 months.
- Patient-specific AML program (ARTEMIS) discontinued due to manufacturing delays; shift to ready-to-use MT-401 from healthy donors.
- Non-dilutive funding secured for off-the-shelf AML program; cash runway extended into Q4 2025.
- Pancreatic cancer Phase 1 IND cleared but advancement pending additional non-dilutive funding.
- MultiTAA T cell therapies shown safe in over 200 patients; no treatment-related adverse events in APOLLO or ARTEMIS.

## SEC filing metadata
- accession: 0001104659-24-002086
- form_type: 8-K
- ticker: MRKR
- cik: 0001094038
- company_name: Marker Therapeutics, Inc.
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1094038/000110465924002086/0001104659-24-002086-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1094038/000110465924002086/tm242285d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-002086
- JSON: https://secwatch.observer/filing/0001104659-24-002086.json
- Plain text: https://secwatch.observer/filing/0001104659-24-002086.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.